According to a research report published by Spherical Insights & Consulting, the microbiome therapeutics market is anticipated to reach USD 4.2 billion by 2035, growing at a CAGR of 38.16% from 2025 to 2035. The United States microbiome therapeutics market is expanding due to increasing FDA approvals, rising prevalence of gastrointestinal disorders, and ongoing advancements in microbiome research. Strategic investments and collaborations are also accelerating the development and commercialization of innovative microbiome-based therapies, driving strong growth and greater adoption in the healthcare sector. The United States microbiome therapeutics market refers to the developing treatments that utilize the human microbiome, a complex community of microorganisms within the body, to prevent and treat various diseases.

According to a research report published by Spherical Insights & Consulting, the microbiome therapeutics market is anticipated to reach USD 4.2 billion by 2035, growing at a CAGR of 38.16% from 2025 to 2035. The United States microbiome therapeutics market is expanding due to increasing FDA approvals, rising prevalence of gastrointestinal disorders, and ongoing advancements in microbiome research. Strategic investments and collaborations are also accelerating the development and commercialization of innovative microbiome-based therapies, driving strong growth and greater adoption in the healthcare sector. The United States microbiome therapeutics market refers to the developing treatments that utilize the human microbiome, a complex community of microorganisms within the body, to prevent and treat various diseases.